**
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Inozyme Pharma’s 8K filing here.
About Inozyme Pharma
Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.
See Also
- Five stocks we like better than Inozyme Pharma
- Top Stocks Investing in 5G Technology
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- How to Use the MarketBeat Stock Screener
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Business Services Stocks Investing
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
